Podcast Series Episode 4: Glaucoma and Zhaoke Ophthalmology's New Treatments

Zhaoke Ophthalmology Named as a “China Top 30 Innovative Small Molecule Drug Developer” on the “2020 China Top 100 Innovative Biotech Companies List”

Zhaoke Ophthalmology’s IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE

Adapalene Clindamycin Hydrochloride Combination Gel Passing The On-Site Inspection For Drug Registration In China

Zhaoke Ophthalmology’s Phase III Clinical Trial of Levobetaxolol Hydrochloride (HCl) Eye Drops for Glaucoma Meets Primary Endpoint